Exelixis | EXEL - Уставный капитал обыкновенных акций





Уставный капитал обыкновенных акций Изменить Дата
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Amgen USD 540M 1000K 2026-03
AstraZeneca USD 1.55B 73K 2026-03
Bayer EUR 982.42M 0 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cytokinetics USD 124.43M 2.17M 2026-03
Eisai JPY 282.11M 0 2026-03
Eli Lilly USD 943.5M 3.33M 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Exelixis USD 253.7M 8.78M 2026-03
Genmab DKK 61.62M 52K 2025-12
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
MacroGenics USD 63.32M 60K 2025-12
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 13M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Takeda JPY 1.58B 241K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Xencor USD 74.06M 2.19M 2026-03